The increases come under the auspices of the agency's user fee program, which aims to cut drug review times and speed new medicines to the U.S. Market.
The PDUFA userfeeprogram has been a great success over the past two decades, as the increased funding from the pharmaceutical companies has allowed the FDA to add about 200 staff members and reduce the drug review process by nearly half.